Benzinga | Nov 3, 2020 09:02AM EST

OncoSec To Present Positive Interim Data From KEYNOTE-695 Trial In Anti-PD-1 Checkpoint Refractory Metastatic Melanoma At SITC 2020 Nov. 9-14

PENNINGTON, N.J. and SAN DIEGO, Nov. 3, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that it will present new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial investigating TAVO(tm) (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA(r) (pembrolizumab) in patients with anti-PD-1 checkpoint refractory metastatic melanoma at the Society for Immunotherapy of Cancer (SITC)'s 35th Anniversary Annual Meeting, to be held virtually from November 9-14, 2020.

The KEYNOTE-695 abstract was selected as one of five studies to be featured in an oral presentation and discussion during the "Virtual Poster Walks" to be held on Tuesday, November 10, time to be determined.

Dr. Paolo Ascierto will also discuss the KEYNOTE-695 data at a Company Symposium entitled, "DNA Plasmid-Based IL-12 Delivered Intratumoral Electroporation: Achieving Meaningful Tumor Response while Avoiding Systemic Toxicities," to be held on November 12 at 7:30 a.m. ET. The Symposium will include presentations from additional key opinion leaders about TAVO and DNA electro-transfer for cancer immunotherapies.

Additionally, OncoSec will be presenting two posters regarding immunological data in metastatic triple negative breast cancer (mTNBC) and preliminary pre-clinical data regarding CORVax12, OncoSec's novel DNA-encodable vaccine for COVID-19. CORVax12 combines TAVO with the National Institute of Health's DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein and is expected to enter a Phase 1 clinical trial in the immediate future given recent IND acceptance.

Details about the presentations and Symposium are as follows:

Oral Presentation -- Poster Walk

Title: Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data

Poster #: 799

Date/Time: Tuesday, November 10, time to be determined.

Presenter: Adil Daud, M.D., HS Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF); Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Symposium

Event Name DNA Plasmid-Based IL-12 Delivered Intratumoral Electroporation: Achieving Meaningful Tumor Response while Avoiding Systemic Toxicities

Date/Time: Thursday, November 12, 2020 from 7:30 -- 8:30 a.m. ET

Presenters:

* Paulo Ascierto, M.D., Director Dept. of Melanoma, Cancer Immunotherapy, Development Therapeutics, Ist. Naz. Tumori IRCCS Pascale

* Deborah Charych, Ph.D., Founder and Chief Technology Officer at RayzeBio

* Richard Heller, Ph.D., Professor at University of South Florida

* Michael Pritchett, D.O. and M.P.H. ,Director of Thoracic Oncology; Director, Chest Center of the Carolinas; FirstHealth of the Carolinas; Pinehurst Medical Clinic Pulmonary & Critical Care Medicine

* Chris Twitty, Ph.D., Chief Scientific Officer (moderator)

Additional Poster Presentations

Title: Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer

Poster #: 789

Date/Time: Wednesday, November 11, 2020 from 5:15--5:45 p.m. ET and Friday, November 13 from 4:40--5:10 p.m. ET

Session: Virtual Poster Hall

Presenter: Erika J. Crosby, Ph.D., Department of Surgery, Duke University Medical Center

Title: Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12

Poster #: 480

Date/Time: Thursday, November 12, 2020 from 4:50--5:20 p.m. EST and Saturday, November 14 from 1--1:30 p.m. EST

Session: Virtual Poster Hall

Presenter Shawn M. Jensen, Ph.D., Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center

Copies of the posters will be archived and available in the Investors section of the Company's website at www.oncosec.com on Nov. 9, 2020.

About KEYNOTE-695